Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 70, Issue 6, Pages 1705-1719Publisher
SPRINGER
DOI: 10.1007/s00262-020-02817-z
Keywords
Lung adenocarcinoma; Immunotherapy; The tumor immune microenvironment; Immune checkpoint inhibitor; Tumor mutation burden; Prognostic model
Categories
Funding
- National Natural Science Foundation of China [81874120,82073370]
- Wuhan Science and Technology Bureau [2017060201010170]
Ask authors/readers for more resources
This study established an immune signature for lung adenocarcinoma (LUAD) patients, showing that patients with low-risk scores had better overall survival, differences in tumor-infiltrating lymphocytes and tumor mutation burden between high and low-risk groups, and a potential predictive relevance with immune checkpoint inhibitor (ICI) therapy.
Background Lung adenocarcinoma (LUAD) is a common pulmonary malignant disease with a poor prognosis. There were limited studies investigating the influences of the tumor immune microenvironment on LUAD patients' survival and response to immune checkpoint inhibitors (ICIs). Methods Based on TCGA-LUAD dataset, we constructed a prognostic immune signature and validated its predictive capability in the internal as well as total datasets. Then, we explored the differences of tumor-infiltrating lymphocytes, tumor mutation burden, and patients' response to ICI treatment between the high-risk score group and low-risk score group. Results This immune signature consisted of 17 immune-related genes, which was an independent prognostic factor for LUAD patients. In the low-risk score group, patients had better overall survival. Although the differences were non-significant, patients with low-risk scores had more tumor-infiltrating follicular helper T cells and fewer macrophages (M0), which were closely related to clinical outcomes. Additionally, the total TMB was markedly decreased in the low-risk score group. Using immunophenoscore as a surrogate of ICI response, we found that patients with low-risk scores had significantly higher immunophenoscore. Conclusion The 17-immune-related genes signature may have prognostic and predictive relevance with ICI therapy but needs prospective validation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available